Jianwei Yang
Fuzhou, 350011, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
An anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) and chemotherapy for RAS/BRAF wild-type metastatic colorectal cancer: A phase Ib study.
Journal: Cancer letters
Published: July 10, 2025
Determinants of Treatment Willingness and Willingness-to-Pay for Lecanemab in China: A Network Analysis.
Journal: Alzheimer disease and associated disorders
Published: May 25, 2025
Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.
Journal: British journal of cancer
Published: April 15, 2025
Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2-positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial.
Journal: EClinicalMedicine
Published: April 14, 2025
A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 07, 2025
Peroxiredoxin 6 in Stress Orchestration and Disease Interplay.
Journal: Antioxidants (Basel, Switzerland)
Published: February 02, 2025
Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II study.
Journal: EClinicalMedicine
Published: January 23, 2025
CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial.
Journal: Nature medicine
Published: December 10, 2024
Pembrolizumab in Patients of Chinese Descent with Microsatellite Instability-high/Mismatch Repair Deficient Advanced Solid Tumors: KEYNOTE-158 Final Analysis.
Journal: Advances in therapy
Published: November 27, 2024
First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study.
Journal: Advances in therapy
Published: August 27, 2024
Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification.
Journal: Clinical and translational science
Published: April 21, 2024
Last Updated: 09/26/2026